{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:49:11Z","timestamp":1698659351018},"reference-count":17,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":497,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2000,8,14]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1. The effects of graded inhibition of nitric oxide synthase (NOS) on blood pressure in the genetically hypertensive (GH) rat strain and NOS activity in regions of the brain (cerebellum, striatum, hippocampus, frontal cortex and medulla oblongata) as a measure of body NOS inhibition were studied.<\/jats:p><jats:p>2. Male GH and normotensive (N) rats (<jats:italic>n<\/jats:italic><jats:bold>=<\/jats:bold> 7\u201310 per group) were given <jats:italic>N<\/jats:italic><jats:sup>G<\/jats:sup>\u2010nitro\u2010\n\t\t\t\t\t<jats:sc>L<\/jats:sc>\u2010arginine methyl ester (\n\t\t\t\t\t<jats:sc>L<\/jats:sc>\u2010NAME; 2, 5, 10 or 20 mg\/kg per day in drinking water) from age 7 weeks. Age\u2010 and weight\u2010matched controls received water only. Systolic blood pressure (SBP) was measured weekly by the tail\u2010cuff method from age 6 weeks. By age 10 weeks, rats were killed and NOS activity was measured.<\/jats:p><jats:p>3. Some GH rats that received over 5 mg\/kg per day <jats:sc>L<\/jats:sc>\u2010NAME developed stroke\u2010like symptoms and were killed before the end of the treatment period.<\/jats:p><jats:p>4. No difference in NOS activity was found between untreated N and GH strains but, in those that received treatment, a graded inhibition was observed with increasing <jats:sc>L<\/jats:sc>\u2010NAME dose levels. The frontal cortex in the GH strain given 20 mg\/kg per day \n\t\t\t\t\t<jats:sc>L<\/jats:sc>\u2010NAME had NOS inhibition of 90% where the N strain had 73% inhibition. Similar results were seen in the other areas of the brain.<\/jats:p><jats:p>5. Left ventricular mass, weight related, was significantly greater in the GH compared with N and was further elevated by treatment with <jats:sc>L<\/jats:sc>\u2010NAME.<\/jats:p><jats:p>6. The SBP at 10 weeks was significantly elevated in GH rats by NOS inhibition with <jats:sc>L<\/jats:sc>\u2010NAME in a dose\u2010dependent manner; 25% for 2 mg\/kg per day, 31% for 20 mg\/kg per day (<jats:italic>P<\/jats:italic> &lt; 0.001). There was a non\u2010significant increase in BP in the N\u2010treated groups (average change of 7.5%).<\/jats:p><jats:p>7. Nitric oxide synthase inhibition causing increased SBP in GH rats suggests an abnormality in the nitric oxide\u2013<jats:sc>L<\/jats:sc>\u2010arginine pathway in this strain.<\/jats:p>","DOI":"10.1046\/j.1440-1681.2000.03299.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T11:07:19Z","timestamp":1047380839000},"page":"647-649","source":"Crossref","is-referenced-by-count":4,"title":["Effects Of Chronic Inhibition Of Nitric Oxide Synthase In The Genetically Hypertensive Rat"],"prefix":"10.1111","volume":"27","author":[{"given":"Elizabeth J","family":"Tucker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet M","family":"Ledingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Laverty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"12","article-title":"Hypertension and its consequences.","volume":"13","author":"Clark D.","year":"1993","journal-title":"N.Z. Pharm."},{"key":"e_1_2_6_3_2","unstructured":"MacMahonS.Blood pressure and the risks of cardiovascular disease. In: Swales JD (ed.).Textbook of Hypertension. Blackwell Science London. 1994; 46\u201357."},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/clinchem\/44.8.1809","article-title":"Role of nitric oxide in cardiovascular disease.","volume":"44","author":"Cannon III RO.","year":"1998","journal-title":"Clin. Chem."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.25.6.1202"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.27.1.36"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00017-9"},{"key":"e_1_2_6_8_2","unstructured":"SimpsonFO PhelanEL LedinghamJM MillerJA.Hypertension in the genetically hypertensive (GH) strain. In: Ganten D de Jong W (eds).Handbook of Hypertension Vol. 16.\u25caExperimental and Genetic Models of Hypertension.Elsevier Science BV Amsterdam. 1994; Ch 11."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.2.682"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1997.tb01217.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.43.6.854"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.32.6.1034"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0890177"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","unstructured":"AkibaY YamaguchiN AmanoHet al.Role of nitric oxide in the control of blood pressure in young and adult spontaneously hypertensive rats.Clin. Exp. Pharmacol. Physiol.1995;22(Suppl. 1): S142\u20133.","DOI":"10.1111\/j.1440-1681.1995.tb02855.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00392-5"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.28.3.367"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00933.x"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1681.2000.03299.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1681.2000.03299.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T13:18:38Z","timestamp":1698585518000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1681.2000.03299.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8,14]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8,14]]}},"alternative-id":["10.1046\/j.1440-1681.2000.03299.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1681.2000.03299.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8,14]]}}}